Your shopping cart is currently empty

CAL-130 Hydrochloride is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $127 | 5 days | 5 days | |
| 5 mg | $249 | 5 days | 5 days | |
| 25 mg | $763 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $992 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $1,490 | 6-8 weeks | 6-8 weeks | |
| 1 mL x 10 mM (in DMSO) | $287 | 5 days | 5 days |
| Description | CAL-130 Hydrochloride is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM). |
| Targets&IC50 | p110β:56 nM, p110δ:1.3 nM, p110α:115 nM, p110γ:6.1 nM |
| In vitro | CAL-130 selectively inhibits the catalytic domains of p110γ and p110δ with IC50s of 1.3 and 6.1 nM, respectively (115 and 56 nM for p110α and p110β), and does not affect other intracellular signaling pathways essential for cell function and survival, such as p38 MAPK or insulin receptor tyrosine kinase. |
| In vivo | The clinical significance of inhibiting PI3Kγ and PI3Kδ activities is assessed by administering CAL-130 to Lck/Ptenfl/fl mice with established T cell acute lymphoblastic leukemia. Candidate mice, exhibiting illness, a white blood cell count above 45,000/μL, blasts on peripheral smear, and >75% Thy1.2 and Ki-67 double-positive circulating cells, receive an oral dose (10 mg/kg) of CAL-130 every 8 hours for 7 days and are monitored until moribund. Despite the limited duration of therapy, CAL-130 effectively extends median survival to 45 days compared to 7.5 days for the control group. |
| Molecular Weight | 462.94 |
| Formula | C23H23ClN8O |
| Cas No. | 1431697-78-7 |
| Smiles | Cl.C[C@H](Nc1nc(N)nc2[nH]cnc12)c1nc2cccc(C)c2c(=O)n1-c1ccccc1C |
| Relative Density. | 1.31g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (108.01 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (7.13 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.